Research programme: Alzheimer's disease therapeutics - Proximagen Neuroscience
Alternative Names: prx 4006Latest Information Update: 15 Aug 2012
Price :
$50 *
At a glance
- Originator Proximagen Neuroscience
- Developer Proximagen
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 15 Aug 2012 Discontinued - Preclinical for Alzheimer's disease in United Kingdom (unspecified route)
- 27 Jul 2005 Preclinical trials in Alzheimer's disease in United Kingdom (unspecified route)